Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA
capex for next 3-4 years: USD100mn (Half from previous capital raise and rest from accruals and customer partnerships) Expect interest cost to half from current levels post repayment of debt Target long term Net Debt-EBITDA of less than 1 (DDC segment) Cartridges capacity expansion: Plan to expand capacity by 5x in coming years from 40mn to 220mn cartridge units Ozempic patient usage is 12 pens per year and Liraglutide usage is 3x of Ozempic Market share in cartridge fill-finish for OneSource could be around 15-20% and target to capture 1/3 rd market share as market forms globally as patents expire Already on-boarded first innovator customer for Microbial in Biologics segment 13 Likes Saptarshi_Chatterjee January 31, 2025, 4:22pm 25 Thanks everybody for such elaborate analysis of the stride/onesource
Water is essential for our bodies to function properly
Studies attempting to investigate the effects of various glucose-lowering drugs on fracture risk are often subject to confounding and insufficient follow-up durations ( For DPP-4is, most studies reported no association with fracture risk ( In the present study, we aimed to investigate fracture risk in individuals using GLP-1 RAs versus individuals using DPP-4is
Fishy Body Odor: A noticeable change in body odor due to the excretion of trimethylamine, a byproduct of L-Carnitine metabolism
Le slnium est un cofacteur de lenzyme glutathion peroxydase